Instrumento Inactivo

Otros idiomas Zealand Pharma A/S Nasdaq

Acciones

ZEAL

US98920Y3045

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Schwach nach Verfall - Tech- und Bankwerte belasten	21/06
Borsa : lo stop di Nvidia frena l'Europa, Milano chiude a -1,1% con banche ko -3-	21/06
Schwach nach Verfall - Tech- und Bankwerte belasten	21/06
Zealand Pharma : le titre flambe, résultats dans l'obésité	21/06
Les actions en mouvement : Atos, Carlsberg, Zealand Pharma et d'autres	21/06
Borse Europa, STOXX 600 in calo, pesano settore tech, banche	21/06
Europe's STOXX 600 falls as tech, banks drag	21/06
European shares open lower as tech losses weigh	21/06
Zealand Pharma Says Petrelintide Drug Reduces Weight in Phase 1b Study	21/06
Zealand Pharma's drug reduces weight by 8.6% in early-stage study	20/06
Zealand Pharma A/S : announces positive topline results from the Phase 1b 16 week multiple ascending dose clinical trial with long acting amylin analog petrelintide	20/06
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide	20/06
Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide	20/06
Health Care Flat as Traders Wait More Obesity-Drug Updates - Health Care Roundup	17/06
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants	13/06
AVIS D'ANALYSTES DU JOUR : Air Liquide, Renault, Rémy Cointreau, Barry Callebaut, Fluidra, Rexel...	10/06
OPINIONI DEGLI ANALISTI DEL GIORNO : Moncler, Postnl, Stellantis, Banco Bpm, Aena, Renault, Sabadell, Barry Callebaut, Hermès, Credito Emiliano...	10/06
Zealand Pharma, Boehringer Ingelheim Weight Loss Compound Hits Midstage Endpoints for Liver Fibrosis	07/06
Zealand Pharma A/S : announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	07/06
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis	07/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Zealand Pharma, ¿un nuevo competidor para Novo Nordisk?

24 de enero 2024 a las 14:23